The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 1.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (20 analysts) rates it buy, with a mean price target of $125.
Charles Schwab Corporation
SCHW · a US exchange · USD · Market cap $184.8B · 33,500 employees
The Charles Schwab Corporation, together with its subsidiaries, operates as a savings and loan holding company that provides wealth management, securities brokerage, banking, asset management, custody, and financial advi…
FAIL · Does not pass the screenAt the last full screen
2026-09-08
Screened 2026-09-08 · the tape above runs as of 22:12 UTC · 11 Sep · two dates, stated on purpose · verdict and workings shown in full · never trimmed
This name holds its markdown label.
Charles Schwab Corporation holds its Markdown at $106.87. The statistical read favours the buyers, held for 7 days.
| Phase | Markdown · caution |
| Quantitative state | The statistical read favours the buyers, held for 7 days |
| Price at the screen | $106.87 |
| Valuation | 19.47 trailing · 13.69 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.75 |
Five Screens, Shown in Full
Does not pass. Business activity screen
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity: Financials sector | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is WorthThe Fair Value Range
Our framework reads AVOID: it trades at roughly a 14% discount to our $121.28 fair value, moderate competitive moat, 20.90% revenue growth.
Fair value range in USD, drawn from the 2026-09-08 screen. The gold marker is the market price at the same screen. A 13.5% margin of safety to the base estimate.
Third-party analyst targets: 20 covering, consensus Buy. The average target sits +17% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & ProjectionsWhere it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-08 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsSchwab's Savings Show Ethical Cracks
When you think of financial services, the image of a local savings and loan holding company might come to mind – a place to tuck away your earnings securely. Charles Schwab Corporation, with its wealth management and brokerage services, is that kind of institution, but with an ethical catch. The company, which operates in the United States and beyond, has been a stalwart in securities brokerage and asset management, yet it has failed our ethical screen, a critical determinant for us at Titan Protect.
Why it stands out, or rather, why we pass, is the glaring ethical failing despite Schwab's robust financial performance. With a forward P/E of 14.1x, robust revenue growth of 21%, and a healthy profit margin of 39%, the numbers suggest a well-run operation. The market consensus is a buy, with a median target of $126, which is above our fair value estimate of $121.28. However, the ethical failing is not something we can overlook, as it goes against our commitment to ethical-first investing.
Risk lies in the ethical shortcomings of Schwab. While the financial metrics paint a picture of a sturdy investment, the failure on our business activity screen is a red flag. The market might be valuing Schwab based on its financial performance alone, but for us, ethical considerations are paramount. This is not a case of financial weakness but of moral risk, which has the potential to erode shareholder value in the long run. Analysis, not advice.
| Forward P/E | 13.7xcheap for a company growing this fast |
| Trailing P/E | 19.5xreasonably valued |
| EPS, trailing | 5.49 |
| EPS, forward | 7.80 |
| Revenue growth | +20.9%strong top-line growth |
| Profit margin | 38.8%highly profitable on every dollar of sales |
| Return on equity | 20.3%an exceptional return on shareholder capital |
| Dividend yield | 144.00% |
| Debt to equity | 1.51a meaningful debt load worth watching |
| Current ratio | 0.66below 1: short-term bills exceed liquid assets |
| Beta | 0.75steadier than the market |
| 52-week range | 83.96 - 114.53 |
| Moat | MODERATE |
| Market cap | $184.8B |
| Employees | 33,500 |
The risks · The things to watch: it carries a real debt load, which raises the stakes if revenue slips.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeSCHW trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (20 analysts) rates it buy, with a mean price target of $116.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (20 analysts) rates it buy, with a mean price target of $116.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 2%. Our forward projection puts the odds of a 10% gain over the next month near 19%. The street (20 analysts) rates it buy, with a mean price target of $116. It reported earnings in this window, a natural checkpoint for the thesis.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Week’s Best: Schwab Hikes Minimums on Popular Tax Strategy Barrons.com · 21h ago
- HOOD Stock Tokens Draw Fresh Scrutiny: Could Regulation Slow Expansion? Zacks · 1d ago
- XRP ETFs Enter Wall Street Repo Market via Schwab Money Fund Collateral CCN · 1d ago
- 2 Growth Stocks to Add to Your Roster and 1 We Brush Off StockStory · 2d ago
- Which Short-Term Bond ETF Is the Better Buy: iShares' ISTB or Schwab's SCHO? Motley Fool · 2d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-08-05 | Schwab-Pomerantz Carolyn | Dir | S - Sale | 18,561 | $1,999,016 |
| 2026-08-05 | Craig Jonathan M. | MD, Head of Retail Investing | S - Sale+OE | 21,750 | $2,327,752 |
| 2026-05-19 | SCHWAB CHARLES R JR. | Chairman of the Board | 27,500 | $2,536,127 | |
| 2026-05-18 | SCHWAB CHARLES R JR. | Chairman of the Board | 27,500 | $2,541,008 | |
| 2026-05-15 | SCHWAB CHARLES R JR. | Chairman of the Board | 5,300 | · | |
| 2026-05-13 | SARIN ARUN | Director | 7,866 | $227,799 | |
| 2026-05-13 | SARIN ARUN | Director | 2,500 | $227,910 | |
| 2026-05-06 | SCHWAB CHARLES R JR. | Chairman of the Board | 218,600 | $20,058,463 | |
| 2026-05-05 | SCHWAB-POMERANTZ CAROLYN | Director | 9,910 | $313,652 | |
| 2026-05-05 | SCHWAB-POMERANTZ CAROLYN | Director | 9,910 | $914,610 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 27 May2026 | John Boozman | Republican | buy | 1K–15K |
| 27 Mar2026 | Alan Armstrong | Republican | buy | 1K–15K |
| 22 Jul2026 | Tony Wied | Republican | buy | 50K–100K |
| 22 Jul2026 | Tony Wied | Republican | buy | 50K–100K |
| 2026-04-13 | Ro Khanna | Democrat | Purchase | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $87.83 | +1.7% | · | $1,017 | +1.7% |
| 2 months | $94.46 | -5.5% | $0.32 | $949 | -5.1% |
| 3 months | $90.91 | -1.8% | $0.32 | $986 | -1.4% |
| 6 months | $96.38 | -7.4% | $0.64 | $933 | -6.7% |
| 1 year | $87.16 | +2.4% | $1.18 | $1,038 | +3.8% |
| 2 years | $72.17 | +23.7% | $2.22 | $1,268 | +26.8% |
| 3 years | $52.73 | +69.4% | $3.22 | $1,755 | +75.5% |
| 5 years | $69.17 | +29.1% | $4.92 | $1,362 | +36.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever SCHW does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.